Fortis says it is ‘complete stranger’ to Daiichi-Singh Brothers dispute after SC allows forensic audit | Shares in focus
AI Summary
Fortis Healthcare's distancing from the legal issues involving the Singh Brothers is a strategic move to reassure investors about its governance and operational integrity. However, the ongoing legal disputes could create a cloud of uncertainty that may dampen investor sentiment and pressure the stock in the short term. Retail investors should remain cautious and monitor developments closely, as any resolution or clarity on the litigation could significantly influence stock performance and market confidence.
Fortis Healthcare said on 27 September that it had no involvement in the ongoing legal dispute between Daiichi Sankyo and the Singh Brothers, stating that it was a “complete stranger” to the matter and played no part in the alleged diversion of the erstwhile promoters’ shareholding.
In an exchange filing on Sunday, the company said it had no control over the transfer of shares by its erstwhile promoters, who owned the shares. It added that it did not receive any money or proceeds from the sale or dilution of the former promoters’ shareholding.
Original Article
Published on Livemint
Frequently Asked Questions
What is this article about?
This is a market news update from Livemint, published on 27 September 2026.
Is this news positive or negative for markets?
TopFund's automated sentiment analysis reads this article as neutral in tone, based on the language used in the report. This is a general signal, not investment advice.
Where can I read the full article?
The full article is available at the original source, Livemint — see the "Read Original Article" link on this page.